Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer

<p>Recurrence per PDL1 and MPR</p>

-д хадгалсан:

Номзүйн дэлгэрэнгүй
Үндсэн зохиолч:	Samuel Rosner (15054884) (author)
Бусад зохиолчид:	Joshua E. Reuss (15054887) (author), Marianna Zahurak (15054890) (author), Jiajia Zhang (15054893) (author), Zhen Zeng (15054896) (author), Janis Taube (15054899) (author), Valsamo Anagnostou (14961731) (author), Kellie N. Smith (15054902) (author), Joanne Riemer (15054905) (author), Peter B. Illei (15054908) (author), Stephen R. Broderick (15054911) (author), David R. Jones (15044613) (author), Suzanne L. Topalian (15031475) (author), Drew M. Pardoll (14953549) (author), Julie R. Brahmer (15054914) (author), Jamie E. Chaft (14937195) (author), Patrick M. Forde (15054917) (author)
Хэвлэсэн:	2025
Нөхцлүүд:	Cancer Immuno-oncology Clinical Research and Trials Clinical Trial Results Immunotherapy Checkpoint blockade Lung Cancer
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!

Ижил төстэй зүйлс